Sanofi (SNY) Total Current Liabilities (2009 - 2026)
Sanofi (SNY) posted Total Current Liabilities of $37.1 billion for Q2 2026, up 12.48% sequentially from $33.0 billion in Q4 2025, and up 12.83% YoY from $32.9 billion in Q2 2025.
Sanofi (SNY) Total Current Liabilities (2009 - 2026) Analysis & Trends
Sanofi has reported Total Current Liabilities for 18 years, with the latest figure at $37.1 billion in Q2 2026.
- Quarterly Total Current Liabilities rose 12.83% year-over-year to $37.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.1 billion (up 12.83% YoY) and the FY2025 annual result came in at $33.0 billion, up 5.88% from the prior year.
- Total Current Liabilities grew to $37.1 billion in Q2 2026 per SNY's latest filing, from $33.0 billion in the prior quarter.
- Over five years, Total Current Liabilities peaked at $37.1 billion in Q2 2026 and troughed at $23.5 billion in Q2 2022.
- A 5-year average of $29.7 billion and a median of $31.2 billion in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities grew 0.4% in 2022, then rose 19.93% in 2024.
- Over 5 years, Total Current Liabilities stood at $24.5 billion in 2022, then advanced by 6.48% to $26.0 billion in 2023, then grew by 19.65% to $31.2 billion in 2024, then increased by 5.88% to $33.0 billion in 2025, then climbed by 12.48% to $37.1 billion in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $37.1 billion, $33.0 billion, and $32.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.03 Bn | 634.27 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 470.29 Bn | 463.72 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 380.80 Bn | 373.66 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 302.80 Bn | 295.11 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 258.24 Bn | 253.34 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 237.40 Bn | 223.41 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 183.07 Bn | 179.89 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 161.54 Bn | 149.84 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.01 Bn | 101.85 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 55.05 Bn | 47.67 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.11 Bn |
| Dec 31, 2025 | 32.99 Bn |
| Jun 30, 2025 | 32.89 Bn |
| Dec 31, 2024 | 31.16 Bn |
| Jun 30, 2024 | 32.34 Bn |
| Dec 31, 2023 | 26.05 Bn |
| Jun 30, 2023 | 26.96 Bn |
| Dec 31, 2022 | 24.46 Bn |
| Jun 30, 2022 | 23.54 Bn |
| Dec 31, 2021 | 24.36 Bn |
| Jun 30, 2021 | 23.03 Bn |
| Dec 31, 2020 | 22.95 Bn |
| Jun 30, 2020 | 20.71 Bn |
| Dec 31, 2019 | 345.90 Mn |
| Jun 30, 2019 | 21.58 Bn |
| Dec 31, 2018 | 19.83 Bn |
| Sep 30, 2018 | 251.24 Mn |
| Mar 31, 2018 | 22.78 Bn |
| Dec 31, 2017 | 18.21 Bn |
| Jun 30, 2017 | 18.75 Bn |